Silvana Lanzalone is a clinician working in Clinical Development – Oncology at Pfizer. She has led clinical trials of a variety of new treatments in different indications and currently, she is the lead clinician on the TALAPRO3 study for men with metastatic Castrate Sensitive Prostate Cancer (mCSPC). She specializes in late phase clinical development and has over 30 years of experience in clinical research. She has contributed to many publications in medical journals on oncology clinical trials and study medications. She earned her degree in Biological Sciences at the University of Milan.